Smallpox Treatment

Global Smallpox Treatment Market to Reach US$73.7 Million by 2030

The global market for Smallpox Treatment estimated at US$66.8 Million in the year 2024, is expected to reach US$73.7 Million by 2030, growing at a CAGR of 1.6% over the analysis period 2024-2030. Antiviral Drugs, one of the segments analyzed in the report, is expected to record a 1.6% CAGR and reach US$32.5 Million by the end of the analysis period. Growth in the Vaccinations segment is estimated at 2.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$18.1 Million While China is Forecast to Grow at 3.0% CAGR

The Smallpox Treatment market in the U.S. is estimated at US$18.1 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$13.5 Million by the year 2030 trailing a CAGR of 3.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.8% and 1.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.0% CAGR.

Smallpox Treatment - Key Trends and Drivers

The medical management of smallpox, a severe infectious disease declared eradicated in 1980, largely focuses on supportive care as no definitive treatment exists. With concerns about its potential use as a bioweapon, the treatment protocol involves isolation of infected patients until all scabs have fallen off to prevent virus transmission. With the FDA`s approval of drugs like tecovirimat in 2018 and brincidofovir in 2021, there has been significant advancement in the therapeutic options available, demonstrating effectiveness in animal studies and approved under protocols for emergency use. The FDA plays a critical role in ensuring the availability of medical countermeasures against smallpox through facilitating drug development and ensuring the safety of the nation`s blood supply. Vaccines like ACAM2000, Jynneos, and the investigational Aventis Pasteur Smallpox Vaccine are crucial in the Strategic National Stockpile, ready for deployment in case of an outbreak. Treatment drugs such as tecovirimat, available in both oral and intravenous forms, and brincidofovir are part of the emergency resources.

Several factors drive the adoption of smallpox treatments and preventive measures despite the eradication of the disease decades ago. Primarily, the persistent threat of bioterrorism where smallpox could be used as a biological weapon significantly influences government policies and healthcare strategies worldwide. This potential threat ensures continued research into and stockpiling of vaccines and antiviral medications. Technological advances in medical research allow for more effective and safer smallpox vaccines and treatments, increasing their adoption. Furthermore, global health security initiatives emphasize the importance of preparedness for potential outbreaks, pushing for advancements in diagnostic and therapeutic options. Public health policies also play a crucial role; they mandate certain protocols for handling outbreaks, which include the maintenance of strategic reserves of vaccines and antivirals. Finally, international cooperation and funding for infectious disease control further support the readiness and availability of smallpox medical countermeasures, reinforcing a global shield against possible future outbreaks.

SCOPE OF STUDY:

The report analyzes the Smallpox Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Treatment Type (Antiviral Drugs, Vaccinations, Supportive Care); End-Use (Hospitals & Clinics End-Use, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 86 Featured) -

• Bavarian Nordic AS
• Chimerix, Inc.
• Emergent BioSolutions Inc.
• Emergex Vaccines
• EpiVax, Inc.
• Oncovir, Inc.
• Pfizer, Inc.
• Sanofi SA
• SIGA Technologies Inc
• Tonix Pharmaceuticals Holding Corp.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.